ARTL
ARTELO BIOSCIENCES (ARTL) Says ART27.13 Matched Semaglutide in Obese Mice
Nonclinical study showed roughly 20% weight loss on Artelo's oral cannabinoid agonist alone and about 40% when combined with semaglutide.
ARTL
Market-moving news on Artelo Biosciences (NASDAQ: ARTL): filings, earnings, deals and other events, from REDFILED.